NCT05669599
MariTide obesity Phase 2
Phase Phase 2
Status Active, not recruiting
Indication Obesity
Enrollment 592
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT05669599
- Phase
- Phase 2
- Status
- Active, not recruiting
- Indication
- Obesity
- Primary completion
- 6/1/2026
- Enrollment (planned/actual)
- 592
- Sponsor
- Amgen
- Peptide
- MariTide
Peptide under study
MariTide
GIPR antagonist / GLP-1 agonist peptide-antibody · Phase 2